Clinical DataSome of the data were encouraging, including strong effects on sorbitol reduction and on a patient-reported outcome, the CMT-Health Index (CMT-HI), especially since these effects were maintained through 24 months.
Market SentimentThe stock is up about 80% during market hours, indicating positive market sentiment based on the clinical trial entry.
Regulatory ApprovalA new clinical trial entry suggests that the company may have aligned on accelerated approval for their drug Govorestat in SORD.